ICU Medical Earns $26.8 Million As Infusion Sales Grow And Margins Widen
The medical-products maker kept its 2026 forecast intact but expects results toward the higher end of its ranges.
ICU Medical, which makes infusion and critical-care products, earned $26.8 million in the third quarter, reversing a year-earlier loss of $3.4 million, according to results furnished with its Thursday SEC filing. Sales increased and gross margins widened, while management left its annual forecast unchanged and said it expects results toward the higher end of its ranges.
More Profit From Growing Sales
Revenue reached $560.4 million, compared with $537.0 million a year earlier. The company's earnings release put growth at 4% as reported and 5% after excluding currency changes, divestitures and certain contract-manufacturing sales.
Gross profit—the revenue remaining after product costs—was $234.8 million, against $200.9 million a year earlier. Gross margin reached 42%, compared with 37%.
Diluted earnings were $1.07 per share, against a loss of $0.14. On the company's adjusted measure, earnings increased to $2.44 per share from $2.03, while adjusted earnings before interest, taxes, depreciation and amortization reached $113.9 million, versus $105.9 million.
The improvement included lower restructuring, transaction and integration expenses: $6.271 million, versus $13.138 million. Net interest expense also fell, to $15.240 million from $19.808 million. The adjusted results excluded tariff refunds, along with items such as stock pay, amortization and product-remediation costs.
Infusion Outpaces Vital Care
Infusion Systems generated $192.5 million in sales, versus $173.9 million a year earlier. Vivek Jain, ICU Medical's chief executive officer, said results were "ahead of our expectations for Infusion Systems" and that the rest of the business generally met expectations.
Consumables remained the largest product line, with revenue of $298.4 million, compared with $285.1 million. Vital Care moved in the opposite direction, recording $69.5 million against $78.0 million.
ICU Medical supplies hospitals, clinics and home-care providers with products including IV pumps, connectors, catheters and respiratory equipment. Its business also includes selling IV solutions for a joint venture in which it owns a 40% interest.
The company sold IV Solutions on May 1, 2025. That operation had been part of Vital Care and supplied $127.4 million of revenue, including contract manufacturing, during the first nine months of 2025. For the first nine months of 2026, total revenue fell 3% as reported, while growth excluding currency effects, divestitures and certain contract-manufacturing sales was 4%.
Cash Builds, Forecast Stays Intact
Third-quarter free cash flow reached $83,417,000, compared with $27,630,000 a year earlier. ICU Medical defines that measure as operating cash flow minus property and equipment purchases, plus proceeds from asset sales; it does not deduct debt-service payments or other obligations.
Operating cash flow for the quarter was $99.586 million, versus $56.710 million. Property and equipment purchases declined to $16.186 million from $29.080 million.
Management continues to forecast 2026 net income of $73 million–$83 million and diluted earnings of $2.89–$3.29 per share. Its adjusted ranges remain $8.60–$9.00 per share and $415 million–$435 million for earnings before interest, taxes, depreciation and amortization.
The stronger quarter changed management's expected position within those ranges—toward the higher end—rather than the forecasts themselves.
Sources
- 8-K Filing — ICU MEDICAL INC/DE (ICUI) — SEC EDGAR
- Exhibit exhibit991q32026er.htm — ICU MEDICAL INC/DE 8-K exhibit — SEC EDGAR
- ICU Medical (ICUI) Beats Q3 Earnings and Revenue Estimates — Yahoo Finance
- ICU Medical (ICUI) Reports Q3 Earnings: What Key Metrics Have to Say — Yahoo Finance
- ICU Medical: Q3 Earnings Snapshot — Associated Press
- ICU Medical (ICUI) Q3 2026 Earnings Call Transcript - The Globe and Mail — theglobeandmail.com
- ICU Medical Announces Third Quarter 2026 Results and — globenewswire.com